Want to see HK:1541 full AI Analyst Report?
1541 Stock Chart & Stats
HK$6.15
HK$0.13(2.58%)
At close: 4:00 PM EST
HK$6.15
HK$0.13(2.58%)
Day’s Range― - ―
52-Week RangeHK$2.80 - HK$16.80
Previous CloseN/A
Volume6.41M
Average Volume (3M)539.71K
Market Cap
HK$2.79B
Enterprise ValueHK$992.18
Total Cash (Recent Filing)HK$946.44M
Total Debt (Recent Filing)HK$363.12M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Mar 30, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding420,477,300
10 Day Avg. Volume321,740
30 Day Avg. Volume539,709
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.73
Price to Sales (P/S)14.37
P/FCF Ratio-10.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$6.28Price Target Upside2.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.9
Revenue Forecast (FY)HK$32.00M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRapid revenue expansion indicates that the company is progressing commercially and gaining traction for its oncology-focused drug portfolio. If this growth continues, increasing scale could improve operating leverage and provide a stronger foundation for future commercialization and earnings development.
Strong Gross ProfitStrong gross profit on reported margins suggests that the company’s products can generate meaningful economic value before operating expenses. As revenue scales, this gross-profit base may help absorb research, development, and corporate costs, supporting a path toward improved profitability.
Moderate Leverage And Positive EquityModerate leverage and a positive equity base provide a comparatively stable capital structure for an early-stage biotechnology business. This balance-sheet position may preserve financial flexibility for continued development activity, even though the company remains loss-making and cash-flow negative.
Bears Say
Persistent Operating LossesLarge EBIT and net losses show that revenue growth has not yet translated into a commercially sustainable operating model. Continued losses can constrain internal funding, require additional capital, and delay the point at which the company’s pipeline meaningfully contributes to durable earnings.
Heavy Cash BurnPersistent negative operating and free cash flow means the business is not yet funding operations from internally generated cash. Ongoing development and commercialization efforts therefore remain dependent on external funding, increasing financial pressure if capital needs stay elevated.
Deeply Negative Returns On EquityA significantly negative return on equity indicates that the company is currently destroying value relative to its invested equity base. Unless operating losses narrow substantially, the existing capital base may continue producing weak returns and limit the effectiveness of future financing.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H News
1541 FAQ
What was ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s price range in the past 12 months?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H lowest stock price was HK$2.80 and its highest was HK$16.80 in the past 12 months.
What is ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s market cap?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s market cap is HK$2.79B.
When is ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s upcoming earnings report date?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s upcoming earnings report date is Mar 30, 2027 which is in 182 days.
How were ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s earnings last quarter?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H released its earnings results on Aug 26, 2026. The company reported -HK$0.444 earnings per share for the quarter.
Is ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H overvalued?
According to Wall Street analysts ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s price is currently Undervalued.
Does ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H pay dividends?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H does not currently pay dividends.
What is ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s EPS estimate?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H have?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H has 420,477,300 shares outstanding.
What happened to ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s price movement after its last earnings report?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H reported an EPS of -HK$0.444 in its last earnings report. Following the earnings report the stock price went up 4.079%.
Which hedge fund is a major shareholder of ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H?
Currently, no hedge funds are holding shares in HK:1541
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
40.93%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (1541) Earnings & Revenues
1541 Stock 12 Month Forecast
Average Price Target
HK$6.28
▲(2.11% Upside)
Technical Analysis
Antengene Corporation Limited
―
Alphamab Oncology
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
CStone Pharmaceuticals
―